Ibudilast: Phase IIa started

MediciNova began a placebo-controlled, U.S. Phase IIa trial to evaluate 100 mg/day ibudilast in about 24 healthy abusers of prescription opioids or heroin. NIH's National Institutes on Drug Abuse (NID...